Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An disease or disorder caused by infection with Histoplasma capsulatum var. duboisii.
Biomarker and diagnostic research for African histoplasmosis has been reported in the published literature.
No clinical trials have been registered for African histoplasmosis.
121 publications have been identified in PubMed for African histoplasmosis. Research spans Review / Meta-Analysis (56%), Basic Science / Preclinical (17%), and Case Report / Case Series (12%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 68 | 56% |
Data assembled from 2 of 12 sources · Last updated Oct 3, 2026, 8:11 PM UTC
Common questions about African histoplasmosis
20 |
17% |
Patient case studies | 14 | 12% |
Disease patterns and progression | 14 | 12% |
Other research | 4 | 3% |
Testing and diagnosis research | 1 | 1% |
Anderson EN (2026). [PMID: 41468891](https://pubmed.ncbi.nlm.nih.gov/41468891/). *Am J Hum Genet*. [Basic Science / Preclinical]
Amado C (2026). [PMID: 40975490](https://pubmed.ncbi.nlm.nih.gov/40975490/). *Ann Allergy Asthma Immunol*. [Review / Meta-Analysis]
Huang Y (2026). [PMID: 41544799](https://pubmed.ncbi.nlm.nih.gov/41544799/). *Metabolism*. [Epidemiology / Natural History]
Kumar KR (2026). [PMID: 41916085](https://pubmed.ncbi.nlm.nih.gov/41916085/). *Curr Opin Immunol*. [Review / Meta-Analysis]
Lázár E (2026). [PMID: 41028908](https://pubmed.ncbi.nlm.nih.gov/41028908/). *Nat Rev Genet*. [Review / Meta-Analysis]
David C (2026). [PMID: 41395910](https://pubmed.ncbi.nlm.nih.gov/41395910/). *Ann Rheum Dis*. [Epidemiology / Natural History]
Venâncio de Barros A (2025). [PMID: 39991370](https://pubmed.ncbi.nlm.nih.gov/39991370/). *Cureus*. [Case Report / Case Series]
El Yamani L (2025). [PMID: 39968428](https://pubmed.ncbi.nlm.nih.gov/39968428/). *Cureus*. [Case Report / Case Series]
Karuntu JS (2025). [PMID: 39733931](https://pubmed.ncbi.nlm.nih.gov/39733931/). *Prog Retin Eye Res*. [Review / Meta-Analysis]
Sahoo SS (2025). [PMID: 39475954](https://pubmed.ncbi.nlm.nih.gov/39475954/). *Blood*. [Review / Meta-Analysis]
AI-curated news mentioning African histoplasmosis
Updated Jul 8, 2026
A new treatment for children aged 2 or older with sickle cell disease has been approved by the U.S. Food & Drug Administration. In a press release on Wednesday, the FDA announced it had approved Casgevy, the first gene therapy for children with sickle cell disease. (NewsNation) — A new treatment for children aged 2 or older with sickle cell disease has been approved by the Food & Drug Administration (FDA). In a Wednesday news release, the FDA announced it had approved Casgevy, the first gene therapy for children with the disease. “Casgevy is a gene therapy consisting of the patient’s own (autologous) hematopoietic (blood) stem cells, administered as a one-time single dose for intravenous infusion,” the release noted. “Pediatric patients as young as 2 years of age can now access a critical additional treatment option to treat these debilitating, life-threatening diseases,” Karim Mikhail, the acting director of the Center for Biologics Evaluation and Research, wrote. “These disorders carry a heavy burden for children and their families, affecting growth, development, and long-term health in profound ways,” Megha Kaushal, acting deputy director of the Office of Therapeutic Products in CBER, said in the release.